The goal of this clinical trial is to understand if an online course in Spanish can help Spanish-speaking parents use Pivotal Response Treatment (PRT) to support language and social skills in young children with Autism Spectrum Disorder (ASD). This study aims to reach families who may have trouble accessing autism services due to language, location, or cost barriers. The main questions it hopes to answer are:
* Can Spanish-speaking parents learn to effectively use PRT techniques to support their child's communication?
* Does this training improve children's language and social interactions?
Researchers will evaluate the effectiveness of the online course for parents who participate in regular virtual check-ins and submit videos showing their practice with PRT.
Participants in the study will:
* Complete online lessons over 12 weeks that teach PRT methods, specifically designed for Spanish-speaking parents
* Meet with a research team member every few weeks by phone or video to ask questions and receive feedback
* Provide video recordings of interactions with their child to track progress
* Complete brief surveys about their experience and child's communication abilities
By focusing on Spanish-speaking families, this study aims to increase access to effective autism support and reduce gaps in care. Researchers hope the findings will help develop better resources for families facing similar barriers and improve language and social outcomes for children with autism.

Start Date01 Dec 2025

Sponsor / Collaborator

Stanford University

[+1]

NCT06852521

/ Enrolling by invitationNot ApplicableIIT

Probing the Role of Feature Dimension Maps in Visual Cognition: Expt 3.1 (Pilot)

How do we know what's important to look at in the environment? Sometimes, we need to look at objects because they are 'salient' (for example, bright flashing lights of a police car, or the stripes of a venomous animal), while other times, we need to ignore irrelevant salient locations and focus only on locations we know to be 'relevant'. These behaviors are often explained by the use of 'priority maps' which index the relative importance of different locations in the visual environment based on both their salience and relevance. In this research, we aim to understand how these factors interact when determining what's important to look at. Specifically, we are evaluating the extent to which the visual system considers locations that are known to be irrelevant when considering the salience of objects. We're testing the hypothesis that the visual system always computes maps of salient locations within 'feature maps', but that activity from these maps is not read out to guide behavior for task-irrelevant locations. We'll have people look at displays containing colored shapes and/or moving dots and report aspects of the visual stimulus (e.g., orientation of a line within a particular stimulus). We'll measure response times across conditions in which we manipulate the presence/absence of salient distracting stimuli and provide various kinds of cues about the potential relevance of different locations on the screen.
The rationale is that by measuring changes in visual search behavior (and thus inferring computations performed on brain representations), we will determine how these aspects of simplified visual environments impact the brain's representation of important object locations. This will support future studies using brain imaging techniques aimed at identifying the neural mechanisms supporting the extraction of salient and relevant locations from visual scenes, which can inform future diagnosis/treatment of disorders which can impact our ability to perform visual search (e.g., schizophrenia, Alzheimer's disease).

Start Date06 Feb 2025

Sponsor / Collaborator

University of California, Santa Barbara

[+1]

NCT06852534

/ CompletedNot ApplicableIIT

Probing the Role of Feature Dimension Maps in Visual Cognition: Expt 1.1 (Behavioral)

How does one know what to look at in a scene? Imagine a "Where's Waldo" game - it's challenging to find Waldo because there are many 'salient' locations in the picture, each vying for one's attention. One can only attend to a small location on the picture at a given moment, so to find Waldo, one needs to direct their attention to different locations. One prominent theory about how one accomplishes this claims that important locations are identified based on distinct feature types (for example, motion or color), with locations most unique compared to the background most likely to be attended. An important component of this theory is that individual feature dimensions (again, color or motion) are computed within their own 'feature maps', which are thought to be implemented in specific brain regions. However, whether and how specific brain regions contribute to these feature maps remains unknown.
The goal of this study is to determine how brain regions that respond strongly to different feature types (color and motion) and which encode spatial locations of visual stimuli extract 'feature dimension maps' based on stimulus properties, including feature contrast. The investigators hypothesize that feature-selective brain regions act as neural feature dimension maps, and thus encode representations of salient location(s) based on their preferred feature dimension. The investigators will collect eye-tracking data while participants view visual stimuli made salient based on different combinations of feature dimensions. From the eye-tracking data, the investigators will construct fixation heat maps on the feature dimensions for all levels of salience, allowing them to connect behavioral data to the latter fMRI dataset. Each participant will freely view the stimuli as they appear on the computer display. Across trials, the investigators will manipulate 1) the 'strength' of the salient locations based on how different the salient stimulus is compared to the background, 2) the number of salient locations, and 3) the feature value(s) used to make each location salient. Altogether, these manipulations will help the investigators fully understand these critical salience computations in the healthy human visual system.

Start Date22 Nov 2024

Sponsor / Collaborator

University of California, Santa Barbara

[+1]

100 Clinical Results associated with University of California, Santa Barbara

0 Patents (Medical) associated with University of California, Santa Barbara

21,096

Literatures (Medical) associated with University of California, Santa Barbara

01 Jan 2026·AGEING RESEARCH REVIEWS

Inflamm-aging as a diverse and context-dependent process: From species and population differences to individual trajectories

Review

Author: Hertel, Johannes ; Tanner, Kamaryn ; Aronoff, Jacob E ; Lemoine, Maël ; Fülöp, Tamás ; Gurven, Michael ; Franck, Maximilien ; Cohen, Alan A ; Daunizeau, Camille ; Trumble, Benjamin C ; Franceschi, Claudio

Inflamm-aging is widely considered a hallmark of aging, yet emerging evidence challenges its universality. Here, we re-examine inflamm-aging through an eco-evolutionary lens, underlining its context dependence across biological scales. Combining mechanistic, evolutionary, comparative, anthropological, genetic, and environmental evidence, we show how fundamental inflammatory mechanisms are integrated and regulated in diverse biological contexts, representing a suite of flexible stress responses. Drawing on studies from non-industrialized populations, which suggest that inflamm-aging reflects mismatches between evolved human biology and industrialized exposomes, we explore how population-specific evolutionary histories and environmental exposures shape differential predispositions and trajectories of inflamm-aging. We propose that, to the extent that inflammation represents this broad suite of stress responses, increases in at least some dimensions of inflammation with age should be nearly universal, as other physiological processes break down and internal stresses mount. However, the particular set of internal stressors that is triggered in a given species, environmental context, or individual is likely more specific, implying that there is unlikely to be any universal signature of inflamm-aging. The question of whether inflamm-aging is universal thus hinges on whether it is defined broadly as any increase in activation of any inflammatory systems, or more narrowly as a particular suite, such as those activated in industrialized populations with high levels of sedentary behavior and cardiometabolic diseases. Inflamm-aging is ultimately a norm of reaction-an aging-related inflammatory profile whose phenotypic expression varies with genotype and environment-and research should therefore focus on understanding how ecological, evolutionary, and environmental factors modulate inflammation and its age-related trajectory.

01 Dec 2025·Seminars in Immunopathology

Maternal microchimeric cell trafficking and its biological consequences depend on the onset of inflammation at the feto-maternal interface

Review

Author: Bramreiter, Bernadette ; Sallinger, Katja ; Kroneis, Thomas ; Slaats, Emiel ; Quilang, Rachel C ; Eikmans, Michael ; Chua, Kristine J

Abstract:

Microchimerism is defined as the presence of a small population of genetically distinct cells within a host that is derived from another individual. Throughout pregnancy, maternal and fetal cells are known to traffic across the feto-maternal interface and result in maternal and fetal microchimerism, respectively. However, the routes of cell transfer, the molecular signaling as well as the timing in which trafficking takes place are still not completely understood. Recently, the presence of inflammation at the feto-maternal interface has been linked with maternal microchimeric cells modulating organ development in the fetus. Here, we review the current literature and suggest that inflammatory processes at the feto-maternal interface tissues are a physiological prerequisite for the establishment of microchimerism. We further propose a spatio-temporal corridor of microchimeric cell migration to potentially explain some biological effects of microchimerism. Additionally, we elaborate on the possible consequences of a shift in this spatio-temporal corridor, potentially responsible for the development of pathologies in the neonate.

01 Dec 2025·MARINE POLLUTION BULLETIN

Out of sight, but not out of mind: Key issues regarding seafloor macrolitter monitoring

Article

Author: Ruiz-Orejón, Luis F ; Huvenne, Veerle A I ; Komorin, Viktor ; Shan, Xiujuan ; Gutow, Lars ; Russell, Josie ; Amon, Diva J ; Consoli, Pierpaolo ; Hanke, Georg ; Giorgetti, Alessandra ; Canals, Miquel ; Angiolillo, Michela ; Wei, Nian ; Cau, Alessandro ; Li, Daoji ; Buhl-Mortensen, Lene ; Palma, Marco ; Zhang, Shoufeng ; Grøsvik, Bjørn Einar ; Liu, Guangpeng ; Woodall, Lucy C ; Ruiz, Marta ; Galgani, Francois ; Jack, Maria Eugenia Molina ; Papatheodorou, George ; Valdenegro-Toro, Matias ; Bergmann, Melanie ; Pham, Christopher Kim ; Nakajima, Ryota ; Lundsten, Lonny ; Martynova, Anastasiia ; Ioakeimidis, Christos ; Pogojeva, Maria ; Davies, Jaime Selina ; Dominguez-Carrió, Carlos ; Palacz, Artur P ; Makarenko, Iryna ; Vinci, Matteo ; Pierdomenico, Martina ; Duarte, Carlos M ; Nattkemper, Tim W

Following a number of meetings devoted to knowledge sharing, identification of key issues, and discussing the best ways to move forward, a wide international expert community is now able to provide recommendations regarding the monitoring of seafloor macrolitter through observation and imaging. As the seafloor constitutes a major sink for marine litter including plastics, it is important to acquire robust and extensive data on litter distribution, abundance, types and size ranges across marine habitats. This should be done through widely agreed, harmonised, and non-destructive methods encompassing advanced technologies. Training and capacity building are essential elements in this endeavour. Both new and legacy imagery are needed to establish baseline assessments and trends. Informing policy-making is indispensable for effective action through upstream and targeted measures, with seafloor macrolitter (and megalitter) being a vital part of the evidence base for global mitigation measures.

News (Medical) associated with University of California, Santa Barbara

23 Oct 2025

·www.prnewswire.com

CAGE Bio Announces Start of Phase 2 Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment

SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ -- CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today announced the initiation of a randomized, double-blind, placebo-controlled clinical trial evaluating its proprietary DNA Aptamer therapy, CGB-600, for the treatment of vitiligo. The investigational active pharmaceutical ingredient, licensed from TAGCyx Biotechnologies Inc., Japan, is a first-in-class DNA Aptamer and new chemical entity specifically designed to selectively bind to interferon gamma and downregulate autoimmune activity implicated in the localized destruction of melanocytes. By targeting disease-specific immune pathways, CGB-600 aims to offer more durable re-pigmentation with fewer side effects compared to existing treatments. "Vitiligo remains an area of high unmet medical need with limited durable treatment options" said Dr. Nitin Joshi, Chief Executive Officer of CAGE Bio. "Our DNA Aptamer program opens an entirely new therapeutic modality in immune-targeted skin therapeutics. Prior preclinical proof-of-concept studies suggest CGB-600 can achieve significant and sustained re-pigmentation. We believe this could be a transformative advancement for patients and providers." "Nucleic acids are large, charged molecules and their localized, topical delivery is a huge unmet need. This human clinical trial, where a drug of this size is being delivered non-invasively into the skin, is a major advancement in the drug delivery field", said Dr. Samir Mitragotri, Professor of Bioengineering at Harvard University, who pioneered the ionic liquid drug delivery platform during his tenure at the University of California, Santa Barbara. He continues to advance the science and application of ionic liquids for therapeutic delivery in his current research at Harvard. About the Phase 2 Clinical Trial The randomized, double-blind, placebo-controlled study will enroll 36 adult patients with nonsegmental facial vitiligo. The primary endpoints are tolerability and improvement in F-VASI (Facial Vitiligo Area Scoring Index) score at Week 24. Top-line results are anticipated in 3Q26. The global vitiligo treatment market is projected to exceed $2 billion in the coming years, but options with sustained benefits remain scarce. Recent advances with JAK inhibitors have expanded possibilities for patients; however, CGB-600 offers a differentiated approach with the potential for enhanced selectivity, lower side effects, and sustained benefits. About CAGE Bio CAGE Bio Inc. is a clinical-stage biotechnology company advancing next-generation dermatology and immunology therapies using nucleic acid and targeted delivery platforms. The company's pipeline includes multiple candidates addressing inflammatory and autoimmune skin disorders. About TAGCyx Biotechnologies Inc. TAGCyx Biotechnologies Inc. is a Japan-based preclinical company specializing in the discovery and optimization of therapeutic oligonucleotide medicines, applying its proprietary unnatural base technology. SOURCE CAGE Bio Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2OligonucleotideImmunotherapy

11 Aug 2025

·www.prnewswire.com

NASA's SpaceX Crew-10 Returns Safely After Completing Dozens of ISS National Lab-Sponsored Investigations

Astronauts wrap up mission after supporting research that could lead to new cancer treatments, more lifelike robotics, space debris removal, and more KENNEDY SPACE CENTER, Fla., Aug. 11, 2025 /PRNewswire/ -- After nearly six months onboard the International Space Station (ISS), the four astronauts of NASA's SpaceX Crew-10 mission have safely returned to Earth. This weekend's splashdown off the coast of California concludes a long-duration science expedition that supported dozens of investigations sponsored by the ISS National Laboratory®. NASA astronauts Anne McClain and Nichole Ayers, Japan Aerospace Exploration Agency (JAXA) astronaut Takuya Onishi, and Roscosmos cosmonaut Kirill Peskov played a vital role in advancing science in space, contributing to biomedical research, physical and materials sciences, technology demonstrations, and student-led experiments. Their work helped push the boundaries of discovery in low Earth orbit to benefit life on Earth and support a sustainable and robust space economy. ISS National Lab-sponsored projects the crew worked on during their mission include the following: A project from the University of Connecticut and Eascra Biotech, in partnership with Axiom Space, is using microgravity to improve the production of Janus base nanomaterials, which could be used to treat diseases like osteoarthritis and cancer. This project builds on previous ISS investigations and is funded through NASA's In-Space Production Applications program. Multiple projects were funded by the U.S. National Science Foundation, which has a long-standing partnership with the ISS National Lab to advance fundamental research on the orbiting laboratory. Rensselaer Polytechnic Institute, in partnership with Tec-Masters, is building on previous research to better understand why protein clumping occurs during pharmaceutical manufacturing—a significant challenge in the industry. Researchers from the University of California, Santa Barbara, in collaboration with Redwire Space Technologies, are studying a liquid separation phenomenon that could be used to create materials for more lifelike robotics. ELVIS may enhance the search for life beyond Earth. Portland State University, in collaboration with NASA's Jet Propulsion Laboratory in Southern California and Teledyne Brown Engineering, Inc., tested a new holographic microscope—the Extant Life Volumetric Imaging System (ELVIS)—that could allow scientists to study the adaptability of life under extreme conditions. Kall Morris Inc, in partnership with Voyager Technologies, leveraged the Astrobee free-flying robots on the space station to validate its REACCH system, which uses tentacle-looking arms with gecko-like adhesive pads to capture floating space debris. REACCH could help protect critical in-orbit infrastructure for Internet communications, weather prediction, GPS, and more. The ISS National Lab is proud to have partnered with NASA and international collaborators to enable this impactful space-based research for the benefit of humanity. The return of NASA's SpaceX Crew-10 mission marks the successful completion of another science expedition in the ongoing effort to leverage space as an innovation platform. To learn more about the science supported by the astronauts during this mission, visit our launch page. Download a high-resolution image for this release: Crew-10 Return About the International Space Station (ISS) National Laboratory: The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory® allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space® (CASIS®) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website. As a 501(c)(3) nonprofit organization, CASIS accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page. SOURCE International Space Station National Lab WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

02 Jun 2025

·www.globenewswire.com

Stratus Therapeutics Strengthens Executive Team with Appointment of Michael P. Cooke, PhD as Chief Scientific Officer

Veteran biopharma executive, Michael P. Cooke, PhD, joins Stratus to accelerate development of its pioneering Stratus Prime™ hematopoietic stem cell platformCAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Stratus Therapeutics, Inc. (“Stratus”), a biotechnology company developing on-demand hematopoietic stem cell (HSC) therapies, today announced the appointment of Michael (Mike) P. Cooke, PhD, as Chief Scientific Officer. A seasoned R&D leader with over 30 years of experience at companies including Vertex Pharmaceuticals, IFM Therapeutics, Magenta Therapeutics, and Novartis, Dr. Cooke brings a proven track record of advancing transformative therapies from discovery through early clinical development. Dr. Cooke’s appointment marks a critical milestone in Stratus’ growth as the company advances its proprietary Stratus Prime™ platform, designed to deliver durable blood and immune system restoration. His deep scientific expertise and leadership in stem cell biology, immunology, and transplant medicine will help drive the development of Stratus’ lead program, ST-101, an on-demand hematopoietic stem cell (HSC) therapy designed to achieve durable, curative outcomes with full immune compatibility and greatly diminish or eliminate the risk of Graft-versus-host disease (GvHD). “We are excited to welcome Mike to the Stratus leadership team, as we bolster our ability to develop off-the-shelf hematopoietic stem cell (HSC) therapies,” said Avanish Vellanki, CEO of Stratus. “Mike’s vast expertise in bone marrow transplant and stem cell biology, along with his passion for transforming scientific discovery into breakthrough therapies, aligns with our mission to make full-system blood and immune restoration available on demand. I know Mike shares our passion to deliver profound global impact across a multitude of indications.” Dr. Cooke added, “I am excited to join Stratus at such a pivotal time. The company’s bold vision to deliver on-demand, immune-compatible stem cell therapies has the potential to fundamentally transform treatment for a wide range of diseases. I look forward to working alongside this talented team to advance the Stratus Prime™ platform and make these innovations a reality for patients.” Dr. Cooke most recently served as Senior Vice President of Cell and Genetic Therapies Research at Vertex Pharmaceuticals, where he led the Cell and Genetic Research Team. Prior to Vertex, he was Chief Scientific Officer at IFM Therapeutics, and previously at Magenta Therapeutics, where he built and led the R&D organization focused on curative therapies in hematologic malignancy, genetic disease, and autoimmunity through bone marrow transplant innovation. Earlier in his career, he held leadership roles at the Genomics Institute of the Novartis Research Foundation (GNF) and SyStemix Inc. Dr. Cooke holds a PhD in Biochemistry from the University of Washington, Seattle, and a BA in Biochemistry from the University of California, Santa Barbara. He has authored more than 60 publications in high-impact journals and serves on multiple scientific boards and advisory committees. About Stratus Therapeutics Stratus Therapeutics is redefining regenerative medicine with Stratus Prime™ — a platform for full hematopoietic system renewal, on demand. Our proprietary product, ST-101, includes both hematopoietic stem cells (Prime HSCs™) and hematopoietic progenitor cells (Prime HPCs™) to drive durable, long-term engraftment with full hematopoietic system restoration, while supporting near-term immune reconstitution. ST-101 is uniquely engineered to deliver a high proportion of Prime HSCs™ in the absence of T-cells, positioning it as a next-generation allogeneic graft, but with immediate availability. ST-101 aims to offer enhanced engraftment outcomes while diminishing the risk of graft-versus-host disease (GvHD). As an off-the-shelf therapy with full HLA immune compatibility, ST-101 aims to eliminate the search associated with finding donors and potentially mitigate the challenges of conventional conditioning regimens. Stratus Therapeutics hopes to position ST-101 as a scalable path to curative blood and immune system replacement. Additional information can be found at www.stratustx.com. Company Contact ir@stratustx.com Investor Contact Dan FerryLifeSci Advisors+1.617.430.7576Daniel@lifesciadvisors.com

Executive ChangeCell Therapy

100 Deals associated with University of California, Santa Barbara

100 Translational Medicine associated with University of California, Santa Barbara

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Nov 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SLC6A4 Inhibitors (UCSF) ( SERT )	Depressive Disorder More	Preclinical
KG-13 ( p53 Y220C )	Neoplasms More	Preclinical
H24 nanoCARs(San Francisco Conservatory of Music/University of California) ( CD72 )	Acute Lymphoblastic Leukemia More	Preclinical
CWHM-12 ( CD51 )	Pulmonary Fibrosis More	Pending
EGFRvIII Targeted CAR-T-UCSF(San Francisco Conservatory of Music/University of California) ( EGFRvIII )	Glioblastoma More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis